

Uppsala, 2018-04-27

PRESS RELEASE

The Dutch investor Nyenburgh Holding B.V. is investing 10,5 MSEK via a directed share issue with up to an additional 21 MSEK through stock options

QuiaPEG Pharmaceuticals Holding AB (publ), "QuiaPEG", announces today that the company has decided on a directed new issue of shares and subscription warrants to the Dutch investment group Nyenburgh Holding B.V., "NYIP".

QuiaPEG Pharmaceuticals Holding AB (the "Company"), listed on AktieTorget, announced today that the Company's board of directors has, on April 26, 2018, resolved with support of authorization from the annual general meeting on March 29, 2017, to carry out a directed new issue of 6 000 000 shares and 6 000 000 subscription warrants.

The new issue of shares include a subscription proceeds totaling SEK 10 500 000. The subscription warrants are issued without consideration and have a term of three years. The subscription price for the subscription warrants totals SEK 3,50 corresponding to approximately 100 percent over the current price level. Upon full future exercising of subscription warrants the Company should be provided with an additional SEK 21 000 000. The issue of shares and subscription warrants are directed to NYIP, which is a Dutch investment group based in Amsterdam that invest in European companies within the life science sector.

The Company intends to use the proceeds from the new issue for, above all, the commercialization of Uni-Qleaver® as well as the development of the Company's internal pharmaceutical projects.

- *We are extremely honored that QuiaPEG has attracted an internationally recognized and financially sound investor of Nyenburgh's caliber and welcome NYIP as a new major shareholder of the Company. With this investment, stability is created and QuiaPEG stands financially well-equipped in the future which means that we can focus on the development of the Company," says Marcus Bosson, CEO, QuiaPEG.*

- *QuiaPEG is a perfect fit in our portfolio, which is focused on highly promising biotech companies in Europe. We believe that QuiaPEGs unique linker technology holds promise in a multitude of applications, ranging from pegylation to antibody-drug-conjugates and fusion proteins. This deal allows us to help finance and expand QuiaPEG for the coming years, in which we expect to see significant value creation and appreciation. We look forward to becoming a major shareholder in QuiaPEG and support the development of the promising Uni-Qleaver® technology, says Dave van Mastwijk, Investment Director, Nyenburgh Holding B.V.*

The main conditions for the new issue of shares

- The Company's share capital shall increase by a maximum of SEK 5 400 000 through a new issue of a maximum 6 000 000 shares.
- Right to subscribe for new shares shall, with deviation from the shareholders' right of first refusal, fall to Nyenburgh Holding B.V.
- The reason for deviation from the shareholders right of first refusal is to reinforce the shareholder faction and the company's future financial possibilities by including a financially sound and international well-embedded and industry familiar actor in the ownership faction and that a directed new issue means higher subscription price, lower costs and an expedited financing process, which all-in-all and with sufficient backing advocates that it is in the Company's and the shareholders' interest to carry out an issue with deviation from the shareholders' right of first refusal.
- The new shares shall be subscribed to at a price of SEK 1,75 per share. The price has been determined with consideration of the share's current listed price and after in-depth discussions with subscribers at arms-length.
- Subscription for new shares shall take place via subscription list that shall be made available to share subscribers. Subscription shall take place at the latest on April 30, 2018. The board of directors shall, however, have the right to extend the subscription period.
- Payment of SEK 1,75 per subscribed share shall be paid in cash at the latest on May 2, 2018. The board of directors shall, however, have the right to push forward the final day for payment.

- The new shares carry the right to dividends the first time on the record day for dividends that is the closest after the new issue has been registered with the Swedish Companies Registration Office and the shares recorded in the share register at Euroclear Sweden AB.
- Upon full subscription of the shares the dilution effect will correspond to approximately 20,9 percent of the share capital and the votes. The dilution effect has been calculated by the number of shares being divided with the sum of the Company's total outstanding shares plus the number of shares proposed to be issued.

The main conditions for the new issue of subscription warrants

- Maximum 6 000 000 subscription warrants entitling to new subscription of shares in the Company shall be issued.
- The right to subscribe to subscription warrants shall, with deviation from the shareholders' right of first refusal, fall to Nyenburgh Holding B.V.
- The subscription warrants are issued without consideration.
- Subscription of the subscription warrants shall take place via subscription list that shall be made available for subscribers. Subscription shall take place at the latest on April 30, 2018. The board of directors shall, however, have the right to extend the subscription period.
- Each subscription warrant entitles to new subscription of 1 share in the Company with a quota value of SEK 0,9, meaning that the share capital can increase by a maximum of SEK 5 400 000 upon full exercising of the subscription warrants through subscription of a maximum of 6 000 000 new shares.
- The subscription warrants can be exercised for subscription of shares in the Company during the period from and including the day for issue of the subscription warrants up to and including April 30, 2021.
- The subscription price per share shall total SEK 3,50 per share.
- Shares that are issued after the subscription according to this terms and conditions carry the right to dividends the first time on the record day for issue that falls the closest after the new issue has been recorded in the share register at Euroclear Sweden AB.

- Upon full exercising of the subscription warrants the dilution effect will correspond to approximately 20,9 percent of the share capital and the votes with consideration taken to full exercising of all outstanding subscription warrants in the Company. The dilution effect has been calculated by the number of subscription warrants divided with the sum of the Company's total outstanding shares (prior to the above new issue of shares) and the number of shares that outstanding subscription warrants can generate.

Reason for deviation from the shareholders' right of first refusal

The reason for deviation from the shareholders' right of first refusal is to reinforce the ownership faction and the Company's future financing possibilities by including a financially sound and industry-embedded actor in the ownership faction and that a directed new issue means higher subscription price, lower costs and an expedited process than a preferential issue, which all-in-all and with sufficient backing according to the board of directors, advocate that it is in the Company's and shareholders' interest to carry out an issue of shares and subscription warrants with deviation from the shareholders' right of first refusal.

Reason for the issue price

The issue of shares and subscription warrants constitute a package offer to NYIP and is conditioned on each other. The share issue price of SEK 1,75 corresponds to a premium of approximately 3,5 percent against the share's volume compensated average price during the latest 15 trading days (SEK 1,6894). The subscription warrants issued have, according to the board of directors' collective assessment, a market value of 17 öre per subscription warrant. All-in-all the issue package directed to Nyenburgh Holding B.V. means an issue discount of approximately 5,88 percent, which has been assessed by the board of directors as being in line with the market in the context.

For further information please contact:

Marcus Bosson

CEO

QuiaPEG Pharmaceuticals Holding AB

Tel: +46 (0) 70 693 12 53
marcus.bosson@quiapeg.com

www.quiapeg.com

Dave van Mastwijk

Head of Investment

Nyenburgh Holding B.V.

+31-655 796 716
mastwijk@nyenburgh.com

www.nyip.nl



This information is such information about QuiaPEG Pharmaceuticals Holding AB (publ) that it is obligated to make public according to EU's market violation regulation. The information was provided for publication on April 27, 2018 through the offices of the above-mentioned contact persons.

About QuiaPEG

QuiaPEG Pharmaceuticals Holding AB (publ) is a development company for pharmaceuticals based on the patented so-called drug-delivery platform, *Uni-Qleaver®*. The Company develops improved and patentable forms of pharmaceuticals under development or that have previously been granted approval by EMA or FDA. These refined and improved forms of pharmaceuticals are built on the company's unique and patented technology platform.

About NYIP

NYIP is a dedicated life science investment partnership based in Amsterdam. We have a strong focus on European life sciences companies that develop innovative solutions for human health. We select and scale our investments based on an efficient and thorough due diligence process that looks at the potential of the innovation being developed.